Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

Several other research analysts have also recently commented on the stock. Daiwa Capital Markets cut shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 ...

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. Separately, see What’s Next ...

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. ABBV stock, with 24% returns ...

I think AbbVie is a fantastic stock to buy for income investors who also like some growth. The company is a Dividend King, with a high forward dividend yield of 3.5%. The stock is also reasonably ...

Shares of AbbVie (ABBV) rose after the biotech firm ... Deckers Outdoor (DECK) was the worst-performing stock in the S&P 500 on concerns about the parent of the Ugg and Hoka brands' current ...

A Look at AbbVie's Guidance and Results ABBV provided 2025 EPS guidance, excluding certain items, of $12.12 to $12.32. Analysts' average estimate heading into the print was just $10.39. Is AbbVie Inc.

AbbVie raised its long-term outlook for Skyrizi and Rinvoq revenue. AbbVie (ABBV) stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm posted better-than-expected ...